PlasmaSelect AG / Joint Venture 21.11.2008 Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PlasmaSelect AG includes Italian affiliates NovaSelect and AltaSelect in joint venture with Diaco S.p.A. New growth and efficiency potential will have positive impact on corporate results Munich, 20.11.2008 PlasmaSelect AG (Securities Code Number 547 180), the Munich-based investment holding company in the healthcare and water treatment market, has achieved a further milestone in advancing its transformation from an operational corporate holding in the healthcare sector into an investment holding company. On 14 November 2008, the Supervisory Board approved a joint venture with the Triest-based Italian Diaco Group. In this, PlasmaSelect will sell its Italian affiliates to an Austrian holding company which will simultaneously acquire Laboratori Diaco Biomedicali S.p.A. ('LDB'), a 100 % subsidiary of Diaco S.p.A. PlasmaSelect will own 40 % of the holding, which will operate under the name of Diaco Medical Group GmbH, while Diaco S.p.A. and an affiliate of Diaco will hold 45% and 15% respectively. The purchase prices are 3 million for AltaSelect, 8 million for NovaSelect and 5 million for LDB, payable over five years from the liquid funds of the holding company. As the purchase prices are slightly below book value, PlasmaSelect anticipates a loss of approximately 1 million from the move. Deconsolidation of the companies will go ahead in the current fiscal year. The action continues PlasmaSelect AG's consistent strategy of generating added value and increasing shareholder value. It marks the approaching completion of the restructuring and reorganization of the company's healthcare division launched three quarters ago. PlasmaSelect anticipates that positive effects from the economies of scale in purchasing and production capacities for the new major name in the infusion solution sector will manifest themselves relatively soon. Thanks to the size of the new company, it will also have the potential to enter new markets and generate additional positive effects on business results in the forthcoming fiscal year. The PlasmaSelect Group will also benefit from Diaco's marketing of high-margin medical technology products. 'We have taken a major step towards our clearly defined goal of generating double-digit operating margins and sustained market positions in the healthcare sector', announces Bernhard Giessel, CEO of PlasmaSelect AG. 'By forming the Diaco Group, PlasmaSelect has succeeded not only in solving the problematic situation of individual subsidiaries, but also in gaining a 40% share of one of the top 5 companies in the infusion solution market. The impetus and market position of the joint venture will have a positive long-term effect on consolidated results for the PlasmaSelect Group.' The managing director of the new parent company of the new joint venture is Pierpaolo Cerani, principal owner of the Diaco Group. The two-man Supervisory Board will include the CEO of PlasmaSelect. Pierpaolo Cerani founded Diaco in 1995 and established the company as one of Italy's leading pharmaceutical and medical technology suppliers. Further information can be downloaded from www.plasmaselect.de under the heading 'Investor Relations'. PlasmaSelect AG Founded in 1998 as a specialist in the sale of infusion and irrigation solutions and complementary medical products, today PlasmaSelect AG is an investment holding company on the healthcare and new technologies market. In addition to the joint venture, the holding currently comprises three operating subsidiaries with a total of almost 200 staff worldwide. In fiscal 2007 (as of 30 November 2007) the company reported consolidated sales of EUR 56.3 million. PlasmaSelect AG is listed on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange (securities ID 547 180). For more information please see www.plasmaselect.de DGAP 21.11.2008 --------------------------------------------------------------------------- Language: English Issuer: PlasmaSelect AG Pettenkoferstraße 22 80336 München Deutschland Phone: +49 (0)89 810 29-0 Fax: +49 (0)89 810 29-111 E-mail: info@plasmaselect.de Internet: www.plasmaselect.de ISIN: DE0005471809, DE0005471809 WKN: 547180, 547180 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Stuttgart, München, Hamburg, Düsseldorf End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: PlasmaSelect AG includes Italian affiliates NovaSelect and AltaSelect in joint venture with Diaco S.p.A.
| Source: EQS Group AG